Fractyl Health is a deeply discounted, binary metabolic-therapy play where late-2026 Revita data could unlock a new post-GLP-1 category, but financing risk and clinical failure could still wipe out most equity value.
Overview
Fractyl Health (NASDAQ: GUTS) is a pre-revenue clinical-stage metabolic therapeutics company developing procedural and gene-therapy approaches for obesity and type 2 diabetes. Its lead asset, Revita, is designed to help patients maintain weight loss after stopping GLP-1 drugs, while Rejuva seeks durable pancreatic hormone production through localized AAV gene delivery. **The core investment case is that Fractyl could define a new post-GLP-1 weight-maintenance category if late-2026 clinical data are positive.** The company reported **$0 revenue in Q1 2026**, reflecting its development-stage status, but consensus projects revenue scaling from $18 million in 2027 to $461 million by 2030 if Revita is cleared and commercialized. Q1 2026 GAAP net income of $9.2 million and EPS of $0.06 looked strong on the surface, but were driven by a $30.1 million non-cash warrant liability revaluation rather than operating profitability. Near-term catalysts are unusually dense: 1-year randomized REMAIN-1 Midpoint data in Q3 2026, topline 6-month registrational REMAIN-1 Pivotal data in early Q4 2026, a potential FDA De Novo submission in late Q4 2026, and initial RJVA-001 human dosing and early data in H2 2026. **The stock offers asymmetric upside, but it is a highly speculative binary setup due to clinical risk, a going-concern warning, and expected financing needs before early 2027.**